In order to develop evidence-based recommendations and expert consensus for the nutritional management of patients with
short bowel syndrome (SBS), we conducted a systematic literature search using the
PRISMA methodology plus a critical appraisal following the GRADE scale procedures. Pharmacological treatment with antisecretory
drugs, antidiarrheal drugs, and
somatostatin contributes to reducing intestinal losses.
Nutritional support is based on
parenteral nutrition; however, oral intake and/or
enteral nutrition should be introduced as soon as possible. In the chronic phase, the diet should have as few restrictions as possible, and be adapted to the SBS type.
Home parenteral nutrition (HPN) should be individualized. Single-lumen
catheters are recommended and
taurolidine should be used for locking the
catheter. The HPN's
lipid content must be greater than 1 g/kg per week but not exceed 1 g/kg per day, and
omega-6 fatty acids (ω6 FAs) should be reduced.
Trace element vials with low doses of
manganese should be used. Patients with chronic SBS who require long-term HPN/
fluid therapy despite optimized treatment should be considered for
teduglutide treatment. All patients require a multidisciplinary approach and specialized follow-up. These recommendations and suggestions regarding nutritional management in SBS patients have direct clinical applicability.